BIO-RAD LABORATORIES INC
For the period ended Dec 31, 2023. Filed Feb 16, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 16, 2024
BIO$386.48-0.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets at
(In thousands, except share data)
| December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $403,815 | $434,215 |
| Short-term investments | 1,203,327 | 1,356,457 |
| Restricted investments | 5,560 | 5,560 |
| Accounts receivable, less allowance for credit losses of $14,926 and $15,029 as of December 31, 2023 and 2022, respectively | 489,017 | 494,645 |
| Inventory | 780,517 | 719,316 |
| Prepaid expenses | 140,040 | 124,179 |
| Other current assets | 26,054 | 23,604 |
| Total current assets | 3,048,330 | 3,157,976 |
| Property, plant and equipment, net | 529,007 | 498,612 |
| Operating lease right-of-use assets | 194,730 | 180,952 |
| Goodwill, net | 413,569 | 406,488 |
| Purchased intangibles, net | 320,514 | 332,147 |
| Other investments | 7,698,070 | 8,830,892 |
| Other assets | 94,850 | 94,599 |
| Total assets | $12,299,070 | $13,501,666 |
(continued)
(In thousands, except share data)
| December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| Current liabilities: | ||
| Accounts payable | $144,625 | $135,041 |
| Accrued payroll and employee benefits | 139,929 | 194,790 |
| Current maturities of long-term debt and notes payable | 486 | 465 |
| Income and other taxes payable | 35,759 | 32,428 |
| Current operating lease liabilities | 40,379 | 36,336 |
| Other current liabilities | 161,621 | 169,648 |
| Total current liabilities | 522,799 | 568,708 |
| Long-term debt, net of current maturities | 1,199,052 | 1,197,716 |
| Deferred income taxes | 1,475,495 | 1,770,481 |
| Operating lease liabilities | 165,478 | 153,597 |
| Other long-term liabilities | 195,113 | 195,912 |
| Total liabilities | 3,557,937 | 3,886,414 |
| Commitments and contingent liabilities | ||
| Stockholders’ equity: | ||
| Class A common stock, $0.0001 par value; 80,000,000 shares authorized; shares issued - 25,169,944 and 25,162,075 at 2023 and 2022, respectively; shares outstanding - 23,422,506 and 24,521,583 at 2023 and 2022, respectively | 2 | 2 |
| Class B common stock, $0.0001 par value; 20,000,000 shares authorized; shares issued and outstanding - 5,095,930 and 5,074,130 at 2023 and 2022, respectively | 1 | 1 |
| Additional paid-in capital | 449,075 | 447,454 |
| Class A treasury stock at cost, 1,747,438 shares at 2023 and 640,492 shares at 2022 | (632,536) | (263,586) |
| Retained earnings | 9,260,629 | 9,898,203 |
| Accumulated other comprehensive loss | (336,038) | (466,822) |
| Total stockholders’ equity | 8,741,133 | 9,615,252 |
| Total liabilities and stockholders’ equity | $12,299,070 | $13,501,666 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.